Q3 2023 INmune Bio Inc Earnings Call

[music].

Greetings and welcome to the immune by the third quarter 2023 earnings call.

At this time all participants are in a listen only mode.

A question and answer session will follow the formal presentation.

Anyone should require operator assistance during the conference. Please pick start Lindsay I hope your telephone keypad.

As a reminder, this conference is being recorded at.

A transcript will follow within 24 hours of this conference call.

At this time it is my pleasure to introduce Mr. David might see if all of Indian buyer, David the floor is yours.

Thank you Claudia and good afternoon, everybody. We thank you for joining us for the for immune <unk> third quarter 2023 financial results.

With me on the call. This doctor RJ Tassie CEO of immune biology, and Dr. Mark Labelle, Chief Scientific officer of immune bio who will provide an update on <unk> in our memory like natural killer cell oncology platform.

Before we begin I remind everyone that except for statements of historical facts. The statements made by management and responses to questions. On this conference call are forward looking statements under the Safe Harbor provisions of the private Securities Litigation Reform Act of 1995.

These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward looking statements.

Please see the forward looking statements disclaimer on the company's earnings press release as well as risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC.

There is no assurance of any specific outcome.

Undue reliance should not be placed on forward looking statements, which speak only as of the date. They are made as the facts and circumstances underlying these forward looking statements may change.

Except as required by law immune bio disclaims any obligations to update these forward looking statements to reflect future information events or circumstances.

With that behind US now I would like to turn the call over to Doctor RJ tests ACF in mobile RJ.

Thank you David and thank you everyone for joining the call as usual I'll arrange my remarks to highlight the key takeaways for the third quarter and the subsequent period and include updates on our platform programs I will start by reviewing our developments of Expro before passing it over to Mark with Dell.

Who will provide an update on <unk> and then David Moss will continue conclude with a discussion of our financial results and provide an update on upcoming and new milestones then we move to Q&A.

During the third quarter, our primary focus remained enrollment of patients into a D O two.

Our blinded randomized phase two trial in patients with early Alzheimer's disease with inflammation.

And we focus on increasing our geographic footprint of that trial. We had notable success on both fronts.

H R E. The U K equivalent of the FDA approved our clinical trial application in August.

Five of the six sites in the U K are already screening and enrolling patients into a D O two.

The U K is an ideal jurisdiction to expand our age Alzheimer's disease trial, given it possesses one of the highest rates of Alzheimer's disease in the western world, coupled with a real burst for profit medical research infrastructure.

Recognition health our lead vendor in the U K has five memory centers with a large rolodex of clinical trial ready patients. This provides a ready pool of patients to screen for participation in the trial.

Recognition house has a history of enrolling a large.

The number of patients and are incentivized to find the right patients to enroll in our program.

Australia, where the trial is furthest advanced continue to see patients who have completed the six month blinded trial and ops into the phase two open label extension program.

We have also submitted regulatory dossiers to additional countries with the plan to have additional sites open soon.

This leaves the U S and the FDA. The FDA is the outlier here, we remain on track with the F. D. A to meet the conditions necessary to lift the clinical hold we believe the hold will be lifted before the end of the year.

There are two main themes.

From the just completed see tad or clinical trials Alzheimer's disease meeting in Boston.

Earlier treatment and better treatments as you can imagine we heard a lot about the anti amyloid therapies little new was presented and no matter how they cut the data there is no change in safety or efficacy.

Of the various anti amyloid products.

Unsurprisingly in that analysis demonstrated all three drugs I can't imagine who can't imagine gone and <unk> performed the same.

This is shaping up to be an interesting marketing battle debating features not benefits.

In my opinion the desire for earlier treatments is driven by the frustrating results from anti amyloid monotherapy.

That is if the results of anti amyloid drugs were better there may be less talk about earlier treatment.

Both of these themes the limit efficacy of anti amyloid drugs in the early treatment.

Play two X pro strengths.

The universe of therapies for Alzheimer's disease is expanding targeting neuro inflammation is high on everyones list Dr. Howard fill it thus chief scientific officer of the Alzheimer's Drug Discovery Foundation.

Delighted the role of inflammation in aging and cognitive decline.

In a recent fierce biotech interviewed Dr. Philip points out that had autopsy beta amyloid is present in the brains of many and elderly and individuals.

That have died with normal cognitive function.

Only those and this is the key point only those with both amyloid and inflammation have dementia and in other words. The immune response to amyloid appears to drive nerve cell death, and synaptic dysfunction that results in cognitive decline.

His comments highlights our long standing position without inflammation, there's no cognitive decline in patients with amyloid pathology.

Combination therapy with the anti amyloid drugs was much discussed at sic, Ted but none at it no data was presented.

Once again the desire for combination therapy reflects a refresh strengthen with the current results.

Combination therapies.

Excuse me.

Must improve safety or efficacy ideally both.

Because the major safety problem with anti amyloid class of drugs is neuro inflammation, we bought I believe X ROE ex pro plays a role in combination therapy.

I mean bio has initiated preclinical studies testing combination therapy and amyloid in animal models.

I am so size the combination therapy is preclinical and in no way dilutes, our focus on the phase II trial currently enrolling patients.

The discussion on early diagnosis focused on blood tests aiming to produce a simple accurate cost effective triage system RV.

Our view is simple cognitive decline as predicted by Biomarkers of neuro inflammation in neuro degeneration blood.

Blood amyloid as a biomarker of disease the disease of Alzheimer's disease.

Beijing by staging I mean, the severity of the disease requires a different set of blood biomarkers.

In my opinion and many of those at the meeting the most promising duo is G. Fast was glial civil Larry acidic protein a biomarker of Astra site activation and fossil Tao $2 17, a biomarker of neuro degeneration are promising.

We do not use G fast or peach out to 17 as screening biomarkers for enrollment.

Excuse me in the phase one trial.

They were measured part as part of the biomarker response package, both biomarkers decreased in patients after treat most of the house with EXPAREL.

We hope to show that this decrease correlates with clinical response in the phase two trial.

We are persistent and I believe the cognitive decline as the sum of synaptic dysfunction in nerve cell death.

Hotel is an excellent measure of neuro degeneration or nerve cell death in patients with Alzheimer's disease measuring synaptic function is more complicated a small group of Alzheimer's patients use a self administered E G.

Using the novel system from Cumulus neuroscience.

The study confirmed in the small number of patients the feasibility of collecting high quality E. G signals at home the patient's life and there was evidence of benefit as demonstrated by acute and chronic exchanges changes in the P 300 amplitudes on EEG after treatment with X Pro Av.

The group is small and the data are early we believe this work is further evidence of improved and synaptic function after X pro treatment.

And future work will correlate this activity with cognitive function and pharmacodynamic responses to DN TNF.

This type of home testing may be a key element to CNS drug development in the future.

Two other applications of the DN TNF family of drugs are worth mentioning new data using India three to treat cancer will be presented at the 30th 38th annual Society of immunotherapy meeting in San Diego later this week M.

N B O three has been shown to be an innate immune checkpoint inhibitor that downregulates serp Alpha surf Alpha that is S. I R. P. Alpha is signal regulatory protein Alpha that has the macrophage side of the CD 47 don't eat me signal.

Downregulates regulation of syrup Alpha re polarized as immunosuppressive macrophages in the tumor micro environment and to M. Two macrophages that directly kill and phagocytes tumors and improves ADC tea, which is antibody dependent cellular five facultative cytosis a.

Key, but often ignored effector of anti cancer antibody therapy.

Recent data from the DMD program confirms the potency of the 10 kilo Dalton piece, our DN TNF in mouse models of the disease as a reminder, the piece our DN TNF compounds.

Are the sons of EXPAREL with similar biologic activity that allows <unk> to expand applications of the DN TNF.

The class of compounds beyond CNS the goals of the M. B O three cancer program in the D. M. D program is to out license these promising drugs.

Some of you are wondering how a.

A single drug dominant negative TNF inhibitors can be useful in the treatment of cancer in the treatment of Alzheimer's disease macros.

Macrophage function is the glue that holds the story together microglia or tissue based macrophages or the brain pans or tumor activated macrophages are tissue based macrophages in the T N me of cancer.

And disease chronic inflammation shall we say stuns the macrophages into not working.

And the brain chronic neuro inflammation causes then micro CLIA to become a dysfunctional phenotype that produces destructive cytokine does not phagocytize cellular and myelin debris and does not prune.

Synapses appropriately this results in nerve cell loss demyelination and synaptic dysfunction.

Hallmarks of Neurodegenerative disease, including Alzheimer's.

DN TNF converts.

The destructive microglia phenotype into our imperative cell type that promotes nerve cell survival demyelination synaptic plasticity.

Remodeling and repair we have seen in the brains of patients with Alzheimer's disease treated with EXPAREL reflect the normalization of microglia function caused by X pro and.

In cancer soluble TNF produced by TNF by tumor cells causes expression of Mark for Serp Alpha and other immunosuppressive cytokines that polarized tambs to an immunosuppressive phenotype that promotes and protects tumor growth and metastasis. These.

These elements promote also promote resistance immunotherapy.

X pro neutralizes soluble TNF, resulting in end two macrophages that do not express serp Alpha kill tumor cells promote a D C P.

On the tumor extra downregulates much forward to expose the tumor to immune attack in summary X pro improves the function of innate immune cells needed to defeat the ravages of Neurodegenerative diseases.

Of the brain and cancer and the nightclub macrophage is the common denominator to these effects.

I will now.

Pass this to Mark with Dell, the founder and CSO of Union vial to update the progress on the <unk> program.

Mark.

Thank you very much RJ and once again I'd like to pause my thanks to those who are listening in and joining this third quarter record. So as you know from the law School to report, we found and I N D with the F. D. A in April this year for a U S trial, I think mean in metastatic castration resistant prostate cancer, we received subsequent.

Parents in May for the use of <unk> in a phase one phase two open label trial across multiple U S centers.

And the response since then from potential clinical sites, there's really been overwhelming we have eight sites already selected to participate in the trial.

It changes and resist criteria using C T scan and bone scan, but as you might imagine these are not expected to change in such a short six months study.

And the U K and Europe with money too advanced for Laurel trial in M. D. S. I M. L. I'm sure you would be if you share with us this extreme frustration and the lack of recruitment in the UK to that trial and this has been due to the changes in the clinical management of these patient in the U K and the new what we'd like to <unk> post Covid era.

When is a man who got type of the first <unk> post COVID-19.

At a meeting of the trials safety Committee held earlier this year the enrollment safety crier criteria was modified in an attempt to limit screening failures appear.

Political amendment was submitted to the image right back in May and finding was approved last week. So we've submitted the revised perch close to the two UK clinical sites for <unk> initiation and the largest cancer center in the UK. The road Marston Hospital has just come online and will be initiated suit.

Meanwhile, the complexities of importing it union to Greece for the great trial on establishing local laboratory monitoring of patients have all been resolved over the summer and the first batch of drug is ready to be delivered to the hospital in Athens a.

Patient has completed screening and it's going to be reviewed on the third of November forest determination finally of suitability for inclusion and treatment. So we hope to close the first cohort with that patient.

We remain very excited about the potential platform as it begins its transition into the treatment of Sony treatments and to remind you. Those are the the tumors that account for approximately 90 per cent of human cancer.

For reasons, we understand most cell therapies currently focus on that 10% of Kansas.

Hematological tumors, but our confidence in the use of ink reunions on achievements is based on good biology.

In vitro data <unk> from my lab sure. Thank <unk>, almost natural killer cells to override the suppression of hypoxia unregulated free cells in the solid in the Chiba microenvironment just solid tumors.

The company presented the data on the England, driven memory like NK cells and the presidential symposium at the annual conference of the International Society of 17 therapy in June and we continue to follow up those data to study Ain't munis sexually NK cells.

The molecular level, you'll hear more on this in the future.

In my previous role as director of the 17 therapy facility at the Royal Free Hospital in University College, London, I spend type of 30 years, producing cell therapies for academic and small spin out company clinical trials.

When they said therapist attempted to enter the commercial world many failed due to manufacturing issues.

So I'm sure you know from the car T story manufacturing a cell therapies as difficult to escape.

But we've solved that problem with a robust and scalable process <unk>, we've been successfully and upscaling the manufacturing process computed completed the validation of that new process to C. G. M P.

We'd sit and sign a contract with a commercial contract manufacturing site and the installation of equipment for that site has now started so we're ready to move out into a commercial manufacturing setting.

This investment paves the way for ambitious plans, but trials and other solid tumors, including ovarian Reno and nasopharyngeal cancer, as we acquire more and more and more of the relevant supporting data.

The company remains committed to execute on his vision of moving forward to most towards commercialization.

Well that ends my update on the platform and I'd like to turn the call over to David Moss CFO discuss the financials. Thank you David.

Super Thank you Mark I'll provide a brief overview of our financial results in upcoming milestones before we head to the Q&A Sessionable.

Net loss attributable to common stock holders for the quarter ended September 30th 2000, twenty-three was approximately $8.6 million compared with approximately $7.7 million for the comparable period and 22.

Research and development expense totaled approximately 6 million for the quarter ended September 30th twenty-three compared with approximately $5.2 million for the comparable period and 22.

General and administrative expense was approximately 2.6 million for the quarter ended September 30th 2023 comparable compared with approximately $2.4 million for the comparable period in 2022.

At September 30th 2023, the company had cash and cash equivalents of approximately $41.8 million.

Based on our current operating plan, we believe caches sufficient under operations until 824.

As of November 1st twenty-three the company had approximately 18 million shares of common stock outstanding.

As highlighted in the prior quarter's industrial call. We continue to focus on achieving our primary clinical trial objectives or remaining cost prudent with a potential recover a portion of R&D expenses in Australia and in the U K.

Now I'd like to move onto our list of upcoming an important milestones.

First milestone that we have which is we hope to have before year end is the removal of the F. D a hold.

Second we expect Tom topline results from our phase two early a D.

Program.

Towards the end of 2024.

Upon release of the F. D. A hold will initiate a phase two trial of X pro in patients with treatment resistant depression.

Additionally, open label Phase one data of Ain't been in high risk M. B M D S and M. L in 2024.

It and the initiation of a face one slash two program and metastatic castration resistant prostate cancer with the first station treated before year end and open label data in 2024.

We expect an upcoming webinar on the use of expert <unk> re myelination and Neurodegenerative disease.

And finally wearing my business development hat for a moment the D. M D market with inconsistent results in gene therapy, and confirmatory trials cracks up skipping drugs still along still long underway it's confusing.

We feel that <unk> could be a novel solution to replace corticosteroids in D. M D.

Corticosteroids, including one approved last week target the same glitter glue <unk> receptor pathway and have the same immunologic metabolic and cosmetic side effects and paradoxically cause muscle atrophy.

Targeting soluble TNF with D N T N F <unk>.

Prevents inflammation and muscle degeneration and promotes muscle regeneration in animal models without evidence of off target safety issues scene with the use of corticosteroids or nonselective T N F inhibitors.

Interestingly TNF as Overexpressed in D. M D at early stages of the disease, where inflammation induces muscle degradation.

Because corticosteroids are the most common drug used to treat D. M. D. A strategy that provides the benefit of corticosteroids without the side effects will benefit all patients with D. M D, regardless of age stage of disease or concomitant therapy.

This is what excites us about the about the D N TNF platform for D. M D.

As always I think our shareholders understand that we continue to pursue business development partnership opportunities for D. N T N. A N D M D and potentially other applications, but there can be no assurance that the company can complete any of these transactions as they are complex and difficult.

In summary.

Management feels that the company has two great platforms and as a small organization with limited resources, we will try to expand the applications of these platforms in order to benefit shareholders.

Naturally will update investors should material business development events occur at this point I'd like to thank you for your time and attention.

Like to turn it back to Claudia to pull for questions Claudia.

Thank you very much Sir at this time, we will be conducting a question and answer session. If.

If you would like to ask a question Keith <unk> and then one on your telephone keypad.

Confirmation tone will indicate your line isn't a question Q you.

<unk> and then two if you would like to live your question from the queue.

Can you let me kill questions to one question and one final question.

Participants evening speaker equipment, it may be necessary for you to pick up your handset before pressing the stock he's.

One moment, please while we <unk>.

The first question comes from <unk> from their teeth proceed with your question job.

Hi, Thanks for answering my questions and congrats on the progress. My first question is an ex pro Uhm can you discuss a little bit more about what gives you confidence clinical hold will be lifted by the end of the year.

[noise] yeah. Thank you Joel RJ here.

Although it took a while to get to an agreement with the F. B I is I think I highlighted at the last call. They gave US a list of things. They wanted done obviously those are those that list was different than any of the other regulatory agencies and we have gone through that list.

The data is you know been completed it as being package and will be sent to the F. D. A four to meet the the goal to have us off hold by the end of the year I you know they they.

Ultimately gave us.

Quite a clear list and we have fulfilled it.

Okay, Great and then as a follow up for the study.

Study in early Alzheimer's or are you able to provide any more information on where you're at and enrollment or what the approximate geographic could end up looking like.

Yeah, I think I <unk> I think you know we mentioned this last time, where we're changing our geography. So quickly that we'd been reluctant to really give names numbers and names yet I think later and early in 2024 whoop when things have kind of.

Settled down I guess, that's the way to describe it we'll be able to give you clear direction on where we are outside of as far as clinical sites. How many sites are involved but.

I would be willing to bet there'll be more than 50 sites open by the end of this process I won't promise that any you'll be in the U S. Because we're really expanding so quickly quickly outside of the U S.

But as we said last time you know this is really setting us up for the phase three trial I mean, it's global.

Multiple continents and I know this has been a very frustrated.

But the one thing we are.

Careful about us we don't want to when we give you enough information we want it to be.

Perfect in other words, we want to be able to back it up and things are just changing so quickly and quite frankly to our advantage and I think the U K is a good example, we have we're ahead of where we expected to be in the UK. They had a great backlog of patients that hopefully will all be screened and many of those will end up.

And the trial.

So all I can say is you all hang tough and you know I think right now we have not changed our guidance, we still expect to be able to provide top line data by the end of the 2024 and I can tell you that everyone. In this company has passed and it got to get us there.

That makes sounds great. Thank you.

Thank you. The next question comes from <unk> from B T. I G. Keith proceed with your question Tom.

Good afternoon, Thanks for holding the call we enjoyed your.

Presentations Ah just to follow up on Joles line of questioning the late 24 data could that be done with no U S participation or are they linked.

So [laughter] yeah, [laughter] it could be done when we're driving forward palm and by the way. Tom. This is RJ. Thank you for the question now it could be done without U S. Participation I mean, you know.

Remember from the time.

Time, let's let me let me use the prostate cancer trial that we're running is a great example.

March said, we got the Green light and I believe it was may.

And we didn't do any font lower front loading planning there because that's expensive and as you know we're careful with our money. So from the time, we got the Green light to the time, we're gonna get our first enrolled patient enrolled will be six to seven months right. That's just what it takes if you go from a standing start alright.

So in the U S. That's what will happen if we once we got a whole will start casting the U S. Net.

By the time those sides get ready to go we may have enrolled the trial now there's a lot of other things. We can do we don't want to frustrate clinical sites.

I couldn't I think I've said, it before or maybe I'm just set it privately.

<unk>.

One of the things that frustrates us is that you know.

Clearly what the F. D. A is doing is different from what are the other regulatory agencies are doing all these other countries. Their patients are getting access to what we think is a pretty good drug expro for Alzheimer's disease.

The U S patients are sitting on the sidelines because of a regulatory challenges, but with the F. D. A.

I can promise you the U S will be involved in a phase three trial and will probably be the main driver of the phase three trial.

But I wouldn't be surprised if we complete the phase two trial without U S stations.

Got it and if I can follow up given we have mark on the line a mark.

Prostate cancer trial, who are these patients are they post taxing.

College Eworld has bent over backwards to try to get prostate cancer to be an immuno reactive.

Tumor that you know extend Ian NEVA went on for years and now it's Nivo EPPY and you see and commune playing there that it might be the final piece to make prostate cancer Nivo reactive is that interesting to you or is this pretty much a mono therapy endeavor for at least awhile.

[laughter], that's a really really excellent question and I would love to spend a long time.

<unk> put my academic Haton. So I think the first Christians yesterday geography plays taxane patients they they.

And stage patients because that's what you always do it if I get <unk> get into phase one trial [laughter].

The question about failure of the checkpoint inhibitors.

Every immunotherapy that's been tried them prostate so far is traven T cell responses.

And leaving suppressive microenvironment at the tumor is is fine whether that be kept by inhibitors or whether it be ah antibody conjugates.

<unk> they failed.

[laughter].

If you look if you read the literature and if you go and speak to a histopathologist they'll tell you that very few if you look at patients who do well in conventional therapy and prostate cancer patients who have a lot of taken K selling food right in that chamber. There there isn't an association with a T cell infantry. So what we're talking in the cells are already in the team and we're just trying to switch the momentarily.

Better like we are in in Am L. A and M. D S and we know who the dirty Little secret about somebody Cuba's is this this thing could neutrophil extra salt of the traps.

The cheaper and they they they inhibit incase, though uhm activity. It means the in case those in the T cells can't get to the trema, well, we're targeting <unk> infiltrating in case other already there so that it becomes part of that problem, but the really interesting thing about these new <unk> and extra side of the trap, So let's stop particularly T cells invading from the periphery.

Blood.

Is that they are broken down by M. T. Macrophages. So one of the great things that might come out to the X profile is that.

Uh Huh mm.

There are three is that you could actually combine those two drugs in a very very nice way to breakdown the traps to enhance the T cell and entry into the cheaper and then respond to the initial response to that this generation by the N K cells of that so I think that's a really exciting combination trauma I'd love to do.

That could also be combined with a checkpoint conventional T. Subtract one inhibitor because once the T cells or that you want to make certain that not not inhibited further by by the inhibitory checkpoints in the in the treatment. So yes, I'd love to think further down the line. We would look at a combination therapy the immune system never works when a single cell there's never been.

Uhm, a cigarette prices, what sir it'd be really really nice to think that we could provide.

Provide a long term benefit by combining these.

[noise] alright, thank you.

Thank you ladies and gentlemen is just another reminder, if you'd like to ask a question piece by Scott and being one if you'd like to ask a question Keith <unk> and then when the next question comes from Daniel Coughing from Tailwinds Research. Please proceed with your question Danielle.

Hey, guys just a couple of follow up questions here regarding inconvenient Uhm and I just saw that am Jim pulled a drug from clinical trials yesterday, and prostate and wrote down about $600 million and I was wondering if you could comment on how that impact your thinking about your program at all if it at all.

Yes, I have a stomach, but I think as much as I said, just now I don't think T cells immediately the onscreen prostate cancer and the the Anticity 47 months, but you're talking about is a good example of that the checkpoint <unk>. The the the N T C D. Three.

Mm combination on 47, so I think we need to look at excuse me [laughter].

We need to look at activating sounds are actually there and so it just makes me more enthusiastic about about the prospects for Ya.

Great and that's what I thought <unk> X Mark and then.

Question about the.

<unk> missed their top line yesterday as well.

I know they they are the leader of D. M. D. Is this is this something that you think might push them towards working with you guys or how do you see that all unfolding with <unk>.

David.

You know that's.

Yeah, you're asking me to guess, let's wrap this going on I can tell you, they're going through probably a pipeline reorganization.

You know I think that you recently had a steroid that was approved that's supposed to be a slightly better steroid than the current standard of care as I spoke about earlier, we believe that X pro going down a completely different pathway, then where steroids that what steroids pathway provides significant benefit over a lot of the <unk>.

Problems that we are that are associated with steroids.

D M D is really an interesting space because.

You know the Exxon skipping drugs, all have confirmation trials, which are still ongoing they're kind of a long been taken a long time, while they can't use drugs on the market. It's gonna be interesting to see what the F. D. A does with the fact that the confirmation trial for the gene therapy.

It's wrapped around his.

You know failed and you know there's there's some thoughts on the street that they keep the Mart they keep the program on on the market.

I don't know what's going to happen My guess is with what the F. D. A has done with regard to that program had been wrong.

So I wouldn't I wouldn't hold any of that water, but the bottom line is is that we feel that.

There needs to be a new approach to D. M D beyond exxon's skipping beyond steroids and beyond gene therapy, and we think that the N T N F. As a really great approach, we like it a lot.

Thanks, Thanks, David that's it for me guys. All my other questions were asked already so thank you.

Yeah.

Thank you very much ladies and gentlemen, we have reached the end of the question and answer session and I'd like to turn the call back to Ya I J for closing remarks. Thank you Sam.

[noise] sure. Thank you a nubile is making progress on two fronts.

Each of our platforms have had a significant increase in shall we say profile and then the last quarter.

With extra we hope to have a therapy that stops the progression of cognitive decline in patients with a D. I.

On this disease.

That's very different than what is offered patience today within communion metastatic casting resistant prostate cancer, we hope to control a disease that and many men can be quiet and the Dylan, but in many as lethal.

We are confident in these ambitious this ambitious goals.

We thank you for your attention today and to those of US that are shareholders. We thank you for your continuing support with that have a good day.

Thank you. This concludes today's conference you may disconnect. Your lines at this time and thank you very much for your participation.

[music].